Trials / Completed
CompletedNCT00573794
Long-term Open-label Safety and Efficacy Study of Adalimumab in Subjects With Ulcerative Colitis
A Multicenter, Open-Label Study of the Human Anti-TNF Monoclonal Antibody Adalimumab to Evaluate the Long Term Safety and Tolerability of Repeated Administration of Adalimumab in Subjects With Ulcerative Colitis
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 592 (actual)
- Sponsor
- AbbVie (prior sponsor, Abbott) · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To assess the long-term safety and maintenance of response of adalimumab in subjects with ulcerative colitis who participated in and successfully completed M06-826 (NCT00385736) or M06-827 (NCT00408629).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | adalimumab | adalimumab prefilled syringes administered as subcutaneous injection EW or EOW |
Timeline
- Start date
- 2007-11-28
- Primary completion
- 2016-12-01
- Completion
- 2016-12-01
- First posted
- 2007-12-14
- Last updated
- 2021-07-07
- Results posted
- 2017-12-19
Source: ClinicalTrials.gov record NCT00573794. Inclusion in this directory is not an endorsement.